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Bacterial resistance to antibiotics is growing up day by day in both community and hospital setting, with a
significant impact on the mortality and morbidity rates and the financial burden that is associated. In the last two
decades multi drug resistant microorganisms (both hospital- and community-acquired) challenged the scientific
groups into developing new antimicrobial compounds that can provide safety in use according to the new
regulation, good efficacy patterns, and low resistance profile. In this review we made an evaluation of present data
regarding the new classes and the new molecules from already existing classes of antibiotics and the ongoing
trends in antimicrobial development. Infectious Diseases Society of America (IDSA) supported a proGram, called
“the ′10 × ´20′ initiative”, to develop ten new systemic antibacterial drugs within 2020. The microorganisms mainly
involved in the resistance process, so called the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and enterobacteriaceae) were the main
targets. In the era of antimicrobial resistance the new antimicrobial agents like fifth generation cephalosporins,
carbapenems, monobactams, β-lactamases inhibitors, aminoglycosides, quinolones, oxazolidones, glycopeptides,
and tetracyclines active against Gram-positive pathogens, like vancomycin-resistant S. aureus (VRSA) and MRSA,
penicillin-resistant streptococci, and vancomycin resistant Enterococcus (VRE) but also against highly resistant Gram-
negative organisms are more than welcome. Of these compounds some are already approved by official agencies,
some are still in study, but the need of new antibiotics still does not cover the increasing prevalence of antibiotic-
resistant bacterial infections. Therefore the management of antimicrobial resistance should also include fostering
coordinated actions by all stakeholders, creating policy guidance, support for surveillance and technical assistance.
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Bacterial resistance to antibiotics is growing up day by
day in both community and hospital setting, increasing
mortality and morbidity [1].
Nowadays, the continuous development and the
spread of bacterial resistances pose some questions
about their future and represent a serious threat for their
clinical utility, leading to an urgent requirement for new
compounds.
Multidrug resistance (MDR) bacteria is defined as
non-susceptibility to one or more antimicrobials on
three or more antimicrobial classes, while strains that
are non-susceptible to all antimicrobials, are classified as
extreme drug-resistant strains [2]. MDR bacteria have a* Correspondence: mattba@tin.it
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reproduction in any medium, provided the orsignificant impact on mortality, hospital stay and
associated-costs [3].
The microorganisms that are mainly involved in
the resistance process are the, so called the ESKAPE
pathogens (Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudo-
monas aeruginosa, and enterobacteriaceae) emphasizing
their capacity to “escape” from common antibacterial
treatments [4].
However despite this scenario, since 2000 only three
new classes of antibiotics have been introduced to the
market for human use and one of those is limited to top-
ical use (Figure 1) [5]. ‘Innovation gap’ is the expression
that has been used to describe the lack of novel struc-
tural classes introduced to the antibacterial armamentar-
ium since 1962.
Numerous agencies and professional societies have
tried to draw attention to the lack of new antibiotics, es-
pecially for MDR Gram-negative pathogens. Since 2004Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and



































Figure 1 Number of approved antibiotics during the last 30 years.
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ments in antibiotic research and development have been
made by the Infectious Diseases Society of America
(IDSA) and several other distinguished societies [6].
Recently, IDSA supported a proGram, called “the ′10 ×
′20′ initiative”, to develop ten new systemic antibacterial
drugs within 2020 through the discovery of new drug clas-
ses, as well as to find possible new molecules from already
existing classes of antibiotics [7].
In this review the new drugs belonging to both old
and new classes of antibiotics will be analysed and
discussed (Table 1).
Cephalosporins
The cephalosporin class of antimicrobial agents is known
for its broad spectrum of activity, proven efficiency and fa-
vorable safety profile, making it the most commonly pre-
scribed class of antimicrobials. There are four recognized
class generations of cephalosporins based on their activity
spectrum. Now with ceftaroline-fosamil and ceftobiprole,
a new subclass of antimicrobials, cephalosporins with
anti-methicillin-resistant Staphylococcus aureus (MRSA)
activity has been introduced. Ceftaroline and ceftobiprole
have also been described in the literature as ‘fifth-gener-
ation’ cephalosporin; however, such classification suggests
a broader Gram-negative profile whereas ceftaroline and
ceftobiprole spectrum of activity is truly unique for its ex-
panded Gram-positive activity beyond all other presently
available cephalosporins (i.e. MRSA).
Ceftaroline fosamil is a new, bactericidal, parental
cephalosporin with expanded Gram-positive activity, in-
cluding vancomycin-resistant S. aureus (VRSA) and
MRSA. Like other beta-lactam antibiotics it works bind-
ing to penicillin-bindings-proteins (PBP) on bacterial cell
walls leading to irreversible inhibition of cell-wall syn-
thesis. The anti MRSA activity is attributed to its ability
to bind PBP 2a with high affinity and to inhibit the activ-
ity of BPB 2a more efficiently than other available beta-lactams [8]. Ceftaroline has activity against Gram-
positive organisms, including S. pneumoniae, S. aureus,
including MRSA and Streptococcus pyogenes, and
Gram-negative species (Haemophilus influenzae and
Moraxella catarrhalis), including resistant phenotypes
[9]. It has been the only Food and Drugs Administra-
tion (FDA) approved cephalosporin with activity against
hetero-resistant vancomycin-intermidiate S. aureus (hVISA),
and vancomycin-resistant S. aureus (VRSA) [10]. Clinical
trials have demonstrated that ceftaroline was non-inferior to
the standard of care for the treatment of community-
acquired pneumonia (CAP) and respectively for skin and
soft structure infections (SSTI). [11,12]. Ceftaroline has been
approved by FDA in 2010 and by European Medical Agency
(EMA) in 2012 for the treatment of acute bacterial SSSIs
and CAP. Ceftaroline was reported to have synergy when
combined with amikacin, tazobactam, meropenem and
aztreonam. Even if several studies have demonstrated low
probability of developing resistance to ceftaroline, this ceph-
alosporin seems to induce AmpC beta-lactamases despite
minimal inhibitory concentration (MIC) values in suscep-
tible range and this is the reason why this cephalosporin
should be avoided against Gram-negative bacteria known to
harbor inducible Amp-C beta-lactamases [13].
The positive attributes of ceftaroline with respect to
antimicrobial stewardship proGrams are: the low poten-
tial for resistance development and the favorable safety
and tolerability profile in clinical trials. Ceftaroline rep-
resents now an interesting agent for the treatment of
cSSSIs and CAP; future studies with intramuscular (im)
formulation should enroll ceftaroline as a potential alter-
native to intravenous (iv) administration in outpatient
setting.Ceftobiprole
Ceftobiprole (formerly BAL9141) is the active compo-
nent of the prodrug BAL5788 (ceftobiprolemedocaril),
Table 1 New antibiotics approved and/or in development
Drug Antibiotic class Spectrum of microbiological activity Main clinical
indication
Development phase
BAL30072 Monocyclic β-lactam MDR P. aeruginosa Acinetobacter including
metallo-ß-lactamases and enterobacteriaceae
NK I
BC-3781 Pleuromutilin Gram-positive, including MRSA cSSSIs II
Besifloxacin Quinolone Gram-positive and Gram-negative ophthalmicinfection Approved by FDA
Biapenem Cerbpenem Gram-negative and Gram-positive RTI, UTI II
CB-182,804 Polimyxin MDR Gram-negative NK I







MDR P. aeruginosaand enterobacteriaceae,
excluding metallo-ß-lactamases
cUTI, cSSTI, VAP III






Gram-negative cIAI, cUTIs, HAP, VAP III
Cethromycin Ketolide Gram-positive and Gram-negative CAP III
Dalbavancin Glycopeptide Gram-positive cSSTI III
Delafloxacin Quinolone Broad-spectrum including fluoroquinolone-
resistant MRSA
cSSTI II
Doripenem Carbapenem Gram-negative cUTIs, cIAIs, HAP, VAP Approved by FDA
and EMA
Eravacycline Tetracycline Gram-negative but not Pseudomonas cIAI II
JNJ-Q2 Quinolone Enhanced Gram-positive activity including
fluoroquinolone-resistance-resistant MRSA
cSSSIs II
ME 1036 Carbapenem Gram-positive, including MRSA and VRE, and
Gram-negatives such ESBL-strains but not P.
aeruginosa
CAP Preclinicaldevelopment
ME1071 Betalactamaseinhibitor Gram-negative I
MK-7655 Betalactamaseinhibitor Gram-negative cIAI, cUTIs II
Nemonoxacin Quinolone Gram-positive and Gram-negative CAP III
Omadacycline Tetracycline Gram-positive and Gram-negative cSSSIs, CAP III
Oritavancin Glycopeptide Gram-positive, including MRSA, VRSA, VRE cSSSIs III








Radezolid Oxazolidinone Gram-positive CAP, SSTI II
Razupenem Carbapenem Gram-negative and Gram-positive cSSSIs II
Solithromycin Gram-positive CAP III
Tebipenem/pivoxil Carbapenem Gram-positive and Gram-negative otolaryngological/RTI II
Tedizolidphosphate Oxazolidinone Gram-positive, including MRSA cSSSIs III
Telavancin Glycopeptide Gram-positive cSSTI, HAP, VAP Approved by FDA
and EMA




NK not known, RTI respiratory tract infections, cSSTI complicated skin and soft tissue infections, cIAI complicated intra-abdominal infections, CAP community
acquired pneumonia, HAP hospital acquired pneumonia, VAP ventilator associated pneumonia, UTI urinary tract infections.
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tivity against Gram-positive bacteria.
Ceftobiprole was refractory to hydrolysis by the com-
mon staphylococcal PC1 beta-lactamase, the class A
TEM-1 beta-lactamase, and the class C AmpC beta-
lactamase, but labile to hydrolysis by class B, class D,
and class A extended-spectrum beta-lactamases, thus
similar to cefepime and ceftazidime patterns of action
[14]. Ceftobiprole and cefepime generally had lower
MICs than ceftazidime for over-expressing AmpC-
producing organisms, such as Enterobacter cloacae.
MICs for all streptococcal species, except the
penicillin-resistant Streptococcus viridans, but including
penicillin-resistant Streptococcus pneumoniae, ranged
from < or = 0.008 to 2.0 mg/L. Ceftobiprole is active
against Enterococcus faecalis (MIC90 = 4 mg/L) but
generally not active against Enterococcus faecium
(MIC90 > 16 mg/L). It also displayed bactericidal activ-
ity against Gram-negative pathogens comparable to
cefepime, ceftazidime or piperacillin-tazobactam in
early studies [15]. Recent data proved activity against
Pseudomonas aeruginosa superior to that of cefepime
[16,17]. A surveillance study on S. pneumoniae called,
TRUST 12, showed that ceftobiprole was the most po-
tent cephalosporin tested against S. pneumoniae with
MIC50 (0,015microg/mL) and MIC90 (0,5microgr/mL)
with values two-fold lower than ceftriaxone [17,18].
Studies of clinical isolates and strains derived from
surveillance studies reported MIC90 values for MRSA
and coagulase-negative Staphylococcus species of 2 to 4
and 0.5 to 8 μg/mL, respectively [19]. Ceftobiprole dem-
onstrated an in vivo activity against a large sample of
community acquired-MRSA clones identified in bone in-
fections [20]. Study in healthy volunteers and in treated
patients did not report the occurrence of significant ad-
verse events [21]. The broad spectrum of activity dem-
onstrated by ceftobiprole in vitro and in vivo suggests
that it may have potential for empirical treatment of
possible Gram-negative and Gram-positive infections,
including those caused by MRSA.
To date, the results of three Phase III clinical trials in-
vestigating ceftobiprole for the treatment of cSSSIs and
hospitalized CAP have been published [22]. In all clinical
and microbiological analyses conducted Ceftobiprole
was non-inferior to the agent compared to, suggesting
for this new cephalosporin a potential role in treating
cSSTI and hospitalized CAP patients.
Ceftobiprole has been approved for use in Canada and
Switzerland, and is under review by regulatory author-
ities in United States, the European Union, Australia,
Russia and South Africa. In November 2008 the FDA
and in 2010 the EMA declined to approve ceftobiprole,
citing data integrity concerns with two of the supporting
studies.Ceftolozane/tazobactam formerly referred to as
CXA-201, is a novel oxyimino-aminothiazolyl cephalo-
sporin (ceftolozane) and β-lactamase inhibitor (tazobactam)
combination being developed for the treatment of serious
Gram-negative infections [23,24]. Ceftolozane showed ex-
cellent in vitro activity against a panel of >900 P.aeruginosa
strains, including cephalosporin- and carbapenem-resistant
isolates. In both the US and Western Europe, Ceftolozane/
Tazobactam (C/T) have proven to be active against the ma-
jority of P.aeruginosa strains whereas resistance occured in
more than 20% of commonly used antibiotics (Cubist: data
on file). In addition to its excellent activity against P.
aeruginosa, C/T demonstrated good to excellent in-vitro
activity against other important Gram-negative organisms,
such as E. coli and K. pneumoniae (Cubist: data on file).
The addition of tazobactam to ceftolozane resulted in an
improved activity compared to other antibiotics such as
ceftazidime.
C/T has completed phase II trials in complicated
intra-abdominal (cIAI) infections (combined with metro-
nidazole). These data have yet not been published. Phase
III trials are ongoing for complicated urinary tract infec-
tion, cIAI and hospital acquired pneumonia (HAP).
Ceftolozane alone has already been studied in phase II
trials for complicated urinary tract infection, where it
performed similarly to ceftazidime among ceftazidime-
susceptible organisms [25].
Given the current in vitro data C/T appears as a very
promising anti-Pseudomonas option.
Carbapenems
Carbapenems have the widest spectrum of antibacterial
activity of all the beta-lactams and provide excellent
coverage of many Gram-negative and Gram-positive aer-
obic and anaerobic bacteria [26].
Similar to penicillin and cephalosporins, carbapenems
are bactericidal agents that bind to the PBPs inhibiting
the bacterial cell wall synthesis. They show less resist-
ance than other beta-lactams because of their stability to
hydrolysis by many extended-spectrum chromosomal
and plasmid-mediated beta-lactamases, including AmpC
and extended-spectrum beta-lactamases (ESBLs).
All the carbapenems already in the market or in devel-
opment are reported in Table 2.
Doripenem is a carbapenem with similar properties to
those of meropenem and a molecular structure that con-
fers beta-lactamase stability and resistance to inactiva-
tion by renal dehydropeptidases [27]. Doripenem was
approved by the FDA in 2007 for the treatment of pyelo-
nephritis, complicated urinary tract infection (cUTI) and
cIA. In Europe was also approved for HAP, including
ventilator-associated pneumonia (VAP) [28-31].
Doripenem is highly active against methicillin-susceptible
Staphylococcus aureus, but not effective against MRSA,
Table 2 Classification of carbapenems in three groups
Group 1 Group 2 Group 3









Activity vs MRSA No No Yes
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(VRE). The action against Enterococcus faecalis is inferior
to that of imipenem, but against pneumococci and other
streptococci is excellent. Its MIC is slightly higher com-
pared to meropenem versus ESBL-producing Klebsiella
pneumoniae, Proteus mirabilis, Serratia spp. Salmonella
spp. and Shigella spp. Against E.coli and Citrobacter it dis-
plays the same efficacy of meropenem. It has lower MICs
than imipenem and meropenem versus Pseudomonas
aeruginosa and Acinetobacter baumannii. It has the lowest
MIC for Burkholderia cepacia compared to the other
carbapenems.
Doripenem is effective against extended-spectrum
β-lactamase or AmpC producers even if poor activity
has been documented against metallo β-lactamases and
class A and D serine carbapenemases [32]; it is also ac-
tive, although less than meropenem, against anaerobic
organisms, except Clostridium species [33].
When doripenem was used in association with colistin,
it showed bactericidal and synergistic action against co-
listin resistant, carbapenemase producing Klebsiella
pneumoniae [34].
To date, the results of five Phase III clinical trials in-
vestigating doripenem for the treatment of cIAI, urinary
tract infections (UTIs) and hospital-acquired pneumo-
nia, including ventilator-associated pneumonia have
been published and demonstrated that doripenem was
non inferior to the standard of care [28-31].
The most common adverse effects of doripenem were
headache, insomnia, gastrointestinal distress, elevated
AST and ALT and phlebitis. Seizures have been shown
to occur less often than with other carbapenems.
The recommended dosage of doripenem is 500 mg
i.v. every 8 hours infused over 4 hour. The dosage
should be decreased in patients with moderate renal
impairment [35].
Recently, the EMA has given new advice for the treat-
ment of patients with HAP. A review of available data
raises concerns that the currently approved dose of
doripenem of 500 mg every 8 hours may not be enaugh
to treat all patients with nosocomial pneumonia,including VAP. For the treatment of patients with im-
paired renal clearance or with non-fermenting Gram-
negative pathogens infections, the Agency’s Committee
for Medicinal Products for Human Use (CHMP) recom-
mends to double the dosage to 1 g every 8 hours (Press
Release- 22/6/2012- European Medicines Agency advises
doctors treating patients with nosocomial pneumonia
with Doribax).
Panipenem is a parenteral carbapenem launched in
Japan, Korea and China for the treatment of urinary
tract infections, lower respiratory tract infections, obstet-
rical/gynaecological and surgical infections.
It is co-administered with the betamipron, an organic
anion tubular transport inhibitor that inhibits panipenem
uptake into the renal tubule. Like other carbapenems,
panipenem has a broad spectrum of activity covering sev-
eral Gram-negative and Gram-positive aerobic and anaer-
obic bacteria.
Many Enterobacteriaceae are highly susceptible to
panipenem, including Escherichia coli, Klebsiella pneu-
monia, Morganella morganii, Proteus mirabilis and
Citrobacter freundii, it has a variable activity against
Serratia marcescens and Providencia rettgeri, but is in-
active against Stenotrophomonas maltophilia.
Against Pseudomonas aeruginosa it shows similar or
less activity compared to imipenem, but less than
meropenem.
It is also effective against MSSA, S. epidermidis and
Enterococcus faecalis, even if, like imipenem, it has lower
activity against Enterococcus faecium and MRSA.
Panipenem proved to have a good activity against anaer-
obes such as Bacteroides fragilis and moderate activity
against Clostridium difficile [36].
Three large trials, in patients with bacterial pneumo-
nia, in respiratory tract infections and UTIs, have been
conducted to compare panipenem/betamiprom with
imipenem/cilastatin: in all three studies it displayed simi-
lar efficiency [37].
It is supplied as 1/1 g administered in two divided doses
by intravenous infusion; in severe infections, the dosage
may be increased to 2 g/2 g in two divided doses. The most
common adverse effects observed with panipenem were
skin rash, diarrhea, eosinophilia and elevation of serum
hepatic transaminases. Co-administration of panipenem/
betamipron and valproic acid (sodium valproate) is contra-
indicated, due to favoring the seizures [37].
Biapenem is a parenteral carbapenem that was
launched in Japan in 2002 and, in USA, is currently in
Phase II study. It displays excellent activity against a
wide range of isolates of Gram-negative and Gram-
positive anaerobes, including b-lactamase-producing
strains. It also has shown a good in vitro activity against
a broad spectrum of Gram-negative, particularly is con-
sidered to be more active than imipenem against most
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spectrum beta-lactamases. However, biapenem showed
variable activity against Serratia marcescens (MIC90
range 0.5 to 8 mg/L) and is inactive against Providencia
rettgeri (MIC90 > 8 mg/L). Although its in vitro activity
against P. aeruginosa seems seems to be similar to that
of imipenem, Biapenem is also active against Gram-
positive bacteria, but not against MRSA and E.faecium.
It shows the same moderate activity against E.faecalis as
imipenem, meropenem and panipenem [38].
In a multicenter, randomized controlled clinical studyit
was compared with imipenem/cilastatin for the treat-
ment of respiratory and UTIs showing the same efficacy
and tolerability profile [39].
This new carbapenem is supplied as 300 mg intraven-
ously administered twice daily. The most common ad-
verse events in comparative clinical trials were skin
eruptions/rashes, nausea, vomiting and diarrhea [40].
Razupenem (also known as SMP-601, PTZ601, PZ-
601, or SM-216601) is a new parenteral carbapenem for
the treatment of complicated skin and soft-tissue infec-
tions [41]. It has a broad-spectrum activity against
Gram-positive and Gram-negative pathogens, includ-
ing MRSA, penicillin-resistant Streptococcus pneumoniae,
vancomycin-resistant E.faecium (VREF), ampicillin-resistant
Haemophilus influenzae, and extended-spectrum ß-lactamase
(ESBL)-producing bacteria even if its activity is reduced
by AmpC enzymes and carbapenemases [41,42].
ME 1036 is an intravenous carbapenem still in clinical
trials. It has in vitro potency against resistant Gram-
positive organisms, including MRSA and VRE, and against
Gram-negatives such ESBL-producing E. coli and K.
pneumoniae, but it is not effective against P. aeruginosa
[43]. Data from a 2009 study have shown its interesting
utility in treating hospitalized patients with bacteraemic
community acquired pneumonia (CAP) [43].
Tomopenem (also known as CS-023) is a new
carbapenem with broad-spectrum activity against Gram-
positive and Gram-negative pathogens for the treatment
of cSSSI and HAP. It displays a good activity against
ceftazidime-resistant Pseudomonas aeruginosa, ESBL-
producing Enterobacteriaceae, penicillin-resistant Strepto-
coccus pneumoniae, H. influenzae and MRSA, with a low
rate of spontaneous resistance [44]. In vitro activity is
comparable to that of imipenem against most Gram-
positive pathogens and similar to meropenem against
Gram-negative isolates even if against MRSA it shows a
better activity (MIC of 4 mg/L) [44,45]. Furthermore after
administration it reaches rapidly the extracellular fluid
thanks to its low degree of protein binding [46].
Tebipenem/pivoxil (TBPM-PI, ME1211) has been
under development as the first oral carbapenem for the
treatment of upper respiratory tract infections. It’s not
active against MBL-producing pathogens and MRSA,meanwhile is active against MDR S. pneumoniae and
other Gram-positives, as well as Enterobacteriaceae like
K. pneumoniae and E. coli [47,48].
Monobactams
Monobactams are β-lactam compounds where in the
β-lactam ring is alone and not fused to another ring (in
contrast to most other β-lactams, which have at least
two rings). They work only against Gram-negative
bacteria.
BAL30072 (SFM) is a new monocyclic beta-lactam
antibiotic currently in Phase I clinical testing, with po-
tent antimicrobial activity against a broad range of
Gram-negative bacteria. It is a siderophore-monobactam
with potent in vitro activity against MDR Gram-negative
bacilli, representing an interesting option in treating
carbapenem-resistant A. Baumanii isolates [49,50]. Ac-
tually it is stable against most carbapenemases including
KPC, metallobeta-lactamases, including the New Delhi
metallo-beta-lactamase 1 (NDM-1), and the class D
carbapenemases, mostly found in Acinetobacter spp. [51].
In a recent study Hofer and colleagues demonstrated
that BAL30072 in association with carbapenem has a syn-
ergic action against P. aeruginosa and Enterobacteriaceae
in interfering with resistance development, particularly in
strains with inducible cephalosporinases [51].
β-lactamase inhibitors
In β-lactam agent/β-lactamase inhibitor combinations,
the latter potentiates the action of the former by
protecting it from enzymatic hydrolysis. Currently used
β-lactam/β-lactamase inhibitor compounds are highly
active against class A and various ESBLs, but with poor
activity against class C and class D enzymes.
Several compounds are now under investigation as po-
tential β-lactamases inhibitors, in different stages of pre-
clinical and clinical studies. They can be classified
according to their molecular structure as β-lactams and
non-β-lactams. Their main advantage over the older
available β-lactamase inhibitors is conferred by the abil-
ity to inhibit class C and D enzymes. Thus, MIC of vari-
ous currently used β-lactams, such as piperacillin or
ceftazidime, is decreased when administered together
with novel β-lactam inhibitors, these antibiotics become
active against ESBL-producing strains. Moreover, used
combined with carbapenems, makes the latter active
against MBL-producing strains.
Even though, the results of studies on clinical useful-
ness of new β-lactam inhibitors are not available yet,
they seem particularly promising as therapeutic agents.
Avibactam (also known as NXL104) is a β-lactamase
inhibitor that has no antibacterial activity, but has inter-
esting property to inhibit beta-lactamases. Currently it is
in clinical development combined with both ceftazidime
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profile against enzymes belonging to classes A and C
β-lactamases (including AmpCs, ESBLs, and KPC) [52],
on the other side, in combination with aztreonam it offers
a potential option against bacteria producing NDM-1 [53].
There are several on-going studies in phase III,
assessing the efficacy in association with ceftazidime in
the treatment of cIAI, HAP and cUTI [54,55].
MK-7655 is a novel beta-lactamase inhibitor under
clinical development. It displays good in vitro activity
against class A and class C carbapenemases, especially
when combined with imipenem/cilastatin. Currently the
drug is in phase II clinical development trial for the
treatment of cIAI and cUTI [56].
ME1071 (CP3242), a class-B inhibitor, maleic acid de-
rivative, is a novel specific inhibitor for metallo-
β-lactamases (MBL). It reduces the MICs of carbapenems
for bacteria with NDM-1 enzyme. It can potentiate the ac-
tivity of carbapenems (expecially biapenem) and ceftazidime
against MBL-producing strains of P. aeruginosaand other
Gram-negative bacteria, as E. coli, Serratia marcescens, A.
Baumanii and K. pneumoniae. It shows less activity against
bacteria with IMP and VIM metallo-enzymes [57].Aminoglycosides
The aminoglycoside class of antibiotics consists of many
different agents. As an example, nine (gentamicin, tobra-
mycin, amikacin, streptomycin, neomycin, kanamycin,
paromomycin, netilmicin, and spectinomycin) are ap-
proved by the FDA and EMA for clinical use in the
United States and Europe. Of these, gentamicin, tobra-
mycin, and amikacin are the most frequently prescribed,
although netilmicin possesses comparable efficacy for se-
lected indications.
The most common clinical indiation (either alone or as
part of combination therapy) of the aminoglycosides is the
treatment of serious infections caused by aerobic Gram-
negative bacilli. While less common, aminoglycosides (in
combination with beta-lactams) have also been used for
the treatment of select staphylococcal and enterococcal
infections.
Relative to other classes of antibiotics, the aminoglycosides
are have demonstrated relative stability against the develop-
ment of resistance. Treatment-emergent resistance (espe-
cially when used in combination with other agents) is rare.
Plazomicin (ACHN-490)is an aminoglycoside with a
bactericidal dose-depending activity that inhibits bacterial
protein synthesis. This new intravenous aminoglycoside
demonstrates activity against Gram-positive and Gram-
negative pathogens [58]. It showed an in vitro synergism
with daptomycin and ceftobiprole against MRSA, hVISA
and VISA and with doripenem, imipenem, piperacillin/
tazobactam and cefepime against P. aeruginosa [59].Phase II study in patients with cUTI and acute pyelo-
nephritis, including cases with concurrent bacteremia,
compared plazomicin with levofloxacin [60].
Quinolones
The quinolone class of antimicrobial agents has gener-
ated considerable interest since its discovery >40 years
ago. Substantial progress has been made in our under-
standing the molecular mechanisms of action of
quinolones against pathogenic bacteria, the induction of
resistance to quinolones in these organisms, and the po-
tential of each quinolone compound to induce toxicity
in treated patients. A number of infectious diseases are
successfully treated with quinolones administered orally
or intravenously, but nowadays its clinical utility is di-
minished due to the widespread of quinolone resistance,
especially in Gram-negative rods. The future of the
quinolones is difficult to predict. Nevertheless, the quin-
olone nucleus continues to provide opportunities for fu-
ture modifications that may produce more valuable
compounds.
Besifloxacin is a topical ophthalmic fluoroquinolone, ap-
proved by the FDA in May 2009 to treat bacterial conjunc-
tivitis caused by susceptible bacterial strains. It is active
against most common ocular bacterial pathogens, including
Staphylococcus aureus, Streptococcus pneumoniae, and Hae-
mophilus influenzae. Among MDR pathogens such as
vancomycin resistant (VR) Enterococcus faecalis and E.
faecium, ciprofloxacin-susceptible MRSA, and ciprofloxacin-
resistant MRSA, MIC90 values were lower than that of other
fluoroquinolones [61].
Nemonoxacin (TG-873870) is a novel non-fluorinated
quinolone in clinical development (phase 3), that displays
a potent in vitro and in vivo activity against CAP patho-
gens. It has a broad-spectrum antibacterial activity, higher
than levofloxacin, against both Gram-positive (S. aureus,
S. capitis, S. pneumoniae and E. faecalis), and Gram-
negative bacteria (E. coli) isolates.
It has also demonstrated a potent antibacterial activity
against ciprofloxacin-resistant MRSA, methicillin- and
levofloxacin-resistant Staphylococcus capitis, penicillin
and levofloxacin-resistant S. pneumoniaeand VRE [62].
It has similar activity to ciprofloxacin, moxifloxacin
and levofloxacin against Enterobacteriaceae. Against P.
Aeruginosa nemonoxacin has similar activity to
moxifloxacin, and the activity against S. maltophilia is
comparable to levofloxacin. Oral nemonoxacin (750 mg
and 500 mg) administered for seven days showed similar
clinical and bacteriological response as levofloxacin in
the therapy of CAP [63,64].
Zabofloxacin (DW-224a) is a novel fluoroquinolone
antibiotic agent, currently in phase II development in
USA. The study which has compared zabafloxacin with
levofloxacin in the treatment of CAP has not been
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blind, randomized, multicenter study in South Korea,
the new quinolone displayed the same clinical and
microbiological results as moxifloxacin in adult patients
with mild-to-moderate CAP. It could be an alternative
in treating acute bacterial exacerbation in chronic ob-
structive pulmonary disease (COPD) [65].
Delafloxacin (RX-3341) is an investigational oral and
parental fluoroquinolone active against a variety of
Gram-positive bacteria, including methicillin- and
quinolone-resistant strains of Staphylococcus aureus
(MRSA, QRSA). It presents also an interesting activity
against quinolone-resistant strains of Pseudomonas
aeruginosa or Klebsiella pneumoniae [66,67].
JNJ-Q2 is a fluorinated 4-quinolone developed for the
treatment of acute bacterial SSTI and respiratory tract in-
fections. In a recent study involving 118 isolates of
Streptococcus pneumoniae, including fluoroquinolone-
resistant variants, it was 32-fold more potent than
moxifloxacin. It has also shown a better action than
moxifloxacin against MRSA. The activity of JNJ-Q2
against Gram-negative pathogens is generally comparable
to those of moxifloxacin. Rates of spontaneous develop-
ment of resistance to JNJ-Q2 in S. pneumoniae, MRSA,
and Escherichia coli were indicative of a lower potential
for resistance selection than other fluoroquinolones [68].
Oxazolidinones
The oxazolidinones are a new class of antimicrobial agents
which have a unique structure and good activity against
Gram-positive pathogenic bacteria. Oxazolidinones are a
class of compounds containing 2-oxazolidine in the struc-
ture. Oxazolidinones represent a new class of synthetic
antibacterial agents active against multiple-resistant
Gram-positive pathogens, including MRSA, penicillin-
resistant streptococci, and VRE.
Oxazolidinones inhibit protein synthesis by binding to
the P site at the ribosomal 50S subunit. Resistance to
other protein synthesis inhibitors does not affect
oxazolidinone activity, however rare development of
oxazolidinone resistance cases, associated with 23S
rRNA alterations, during treatment have been reported.
Linezolid, the first and at the moment the only
oxazolidinone available, has already taken its place in the
clinical setting for the treatment of Gram-positive infec-
tions. Pharmacokinetic properties as well as its good
penetration and accumulation in the tissue including
skin, bone, lung, vegetations, haematoma and cerebro-
spinal fluid, allow its use for several type of infections.
Tedizolid phosphate (TR-701), previously known as
torezolidphosphate, is an inactive prodrug that, after oral
or intravenous administration, is rapidly converted to
the active form (torezolid). Tedizolid is a new
oxazolidinone designed for the treatment of infectionscaused by Gram-positive bacteria with resistance to
penicillin and other antimicrobial classes; it showed
an improved antibacterial efficacy, especially against
linezolid-resistant strains [69]. Tedizolid has high bio-
availability, penetration, and tissue distribution when
administered orally or intravenously. The activity of
tedizolid was better than linezolid’s against strains of
Staphylococcus spp., Streptococcus spp., and Entero-
coccus spp. in vitro studies, including strains resistant
to linezolid and those not susceptible to vancomycin
or daptomycin. Choi and collegues showed that
tedizolid is four-fold more potent in vitro than
linezolid against S. pnemoniae penicillin resistant [70].
Its pharmacokinetic characteristics allow an once-
daily administration that leads to a more predictable
efficacy and safety profile than those of linezolid. No
hematological adverse effects have been reported asso-
ciated with tedizolid when used at the therapeutic
dose of 200 mg in Phase I, II, or III clinical trials of up
to 3 weeks of tedizolid administration. Given that the
clinical and microbiological efficacy are similar for the
200, 300, and 400 mg doses, the lowest effective dose
of 200 mg once daily for 6 days was selected for Phase
III studies in acute bacterial skin and skin-structure
infections, providing a safe dosing regimen with low
potential of developing myelosuppression. Unlike
linezolid, tedizolid does not inhibit monoamine oxi-
dase in vivo, therefore interactions with adrenergic,
dopaminergic, and serotonergic drugs are not to be
expected [71].
Tedizolid has been compared with linezolid in a phase
III study in the treatment of acute bacterial SSTI. A
short (6-day) course of tedizolid was as effective as a 10-
day course of linezolid with regard to both early and
sustained clinical responses [72].
Radezolid (RX-1741)
The goals of the development proGram of this new
oxazolidinone included expansion of the spectrum to in-
clude fastidious Gram-negative bacteria that would fa-
cilitate empirical treatment of community-acquired
pneumonia, as well as optimization of drug-like prop-
erties. The antimicrobial activity of radezolid was
evaluated against respiratory pathogens demonstrat-
ing significant better activity than linezolid with
anMIC90 of 0.25 mcg/mL against both S. Pneumonia
and S. pyogenes. MIC90 values for staphylococci ranged
from 1–4 mcg/mL and 0.5–1 mcg/mL for enterococci
[73]. Radezolid was clearly differentiated from linezolid
and the other oxazolidinones versus Haemophilus
influenzae and Moraxella catarrhalis, with an MIC90 of 1
mcg/mL and 0.5 mcgg/mL, respectively [72]. Radezolid
has outperformed linezolid in an E. faeciumVanA periton-
itis model when dosed [74].
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two phase 2 clinical trials completed to date: the first in
CAP and the second trial in cSSSI [75].
Radezolid offers the potential for several incremental
improvements in that it is generally two-fold more ac-
tive in vitro than linezolid against the staphylococci and
4- to 16-fold more potent against the streptococci and
enterococci. Unique for the oxazolidinones, radezolid
offers coverage of the fastidious Gram-negative organ-
isms. It is unclear at this point, based upon published
literature, whether radezolid has any appreciable safety
advantages over linezolid. To date, phase III trials have
not been initiated.
Glycopeptides
Glycopeptide antibiotic are large, rigid molecules that in-
hibit a late stage in bacterial cell wall peptidoglycan syn-
thesis. They bind to the amino acids within the cell wall
preventing the addition of new units to the peptidogly-
can. In particular, they bind to acyl-D-alanyl-D-alanine
in peptidoglycan.
These antibiotics are effective mainly against Gram-
positive cocci. They exhibit a narrow spectrum of action.
Some tissues are not penetrated very well by old glyco-
peptides and they do not penetrate into the cerebro-
spinal fluid. Several derivates of vancomycin are
currently being developed, including oritavancin and
dalbavancin (both lipoglycopeptides). Possessing longer
half-lives than vancomycin, these newer candidates may
demonstrate improvements over vancomycin due to less
frequent dosing and activity against vancomycin-
resistant bacteria.
Oritavancin is a semisyntetic lipoglycopeptide analogue
of vancomycin with at least 3 mechanisms of actions:
inhibition of transglycosylation, inhibition of trans-
peptidation and cell memebrane distruption/interaction
[76,77]. Oritavancin seems promising for the treatment of
serious infections caused by Gram-positive bacteria, such
as MRSA, VISA, VRSA, daptomycin-nonsusceptible S.
aureus and VRE. Recent data collected in Western Europe
confirm the potent in vitro activity of oritavancin against a
wide range of resistant MRSA, MRCoNS and VRE iso-
lates [76]. Oritavancin present a rapid concentration-
dependent bactericidal activity. The pharmacodynamic
(PD) and pharmacokinetic (PK) profiles of oritavancin
are unique and suggest that oritavancin could be ef-
fective given in a single dose. A humanized dosing
regimen mimicking a 1,200-mg single dose of
oritavancin administered to neutropenic mice with S.
aureus thigh infections resulted in a greater rate and
spread of bacterial kill than did a regimen simulating
400 mg once daily for 3 days, indicating that a front-
loaded dose of oritavancin could provide for faster and
more sustained bacterial killing activity than anequivalent cumulative dose administered in a fraction-
ated manner [78]. Oritavancin is not metabolized fol-
lowing i.v. dosing. Instead, it is slowly excreted,
unchanged, in both urine and the feces (terminal half-
life = 393 ± 73.5 h), which means that no dosage ad-
justment is required for age, or for renal or mild to
moderate hepatic dysfunction.
In two phase 3 studies evaluating the efficacy of
oritavancin in treating cSSSI when dosed daily for 3 to
7 days oritavancin was non-inferior to the agent com-
pared to.
The SIMPLIFI study was designed to evaluate the
non-inferiority of two front-loaded treatment regimens
(a single dose and an infrequent dose on day 1with an
optional dose on day 5) to the daily-dose regimen used
in the previous phase 3 studies for the treatment of
cSSSI due to Gram-positive pathogens. The results of
this study show that single- and infrequent-dosing
schedules of oritavancin were as efficient as daily ad-
ministration and had a similar safety profile in treating
cSSSI caused by Gram-positive pathogens, including
MRSA [79,80].
Telavancin is a vancomycin-derived lipoglycopeptide
administered once-daily and characterized by a broad-
spectrum of microbiologic activity against Gram-positive
bacteria. Telavancin has a fast bactericidal activity and
multiple mechanisms of action. Telavancin exhibits po-
tent in vitro antibacterial activity against a broad range
of clinically important Gram-positive bacteria, including
MRSA. The unique structure of telavancin, which is de-
rived from vancomycin with the addition of a hydropho-
bic side chain and a hydrophilic group (precisely a
glycolipopeptidic structure), is responsible for the im-
proved activity against isolates with reduced glycopep-
tide susceptibility [81,82].
The excellent activity of telavancin against Staphylo-
coccus spp. represents the main characteristic of this
compound. MIC values (MIC90) of tested strains
between 0.25 and 1 mg/L have been reported in an over
4,500 isolates of methicillin-susceptible S. aureus
(MSSA) and MRSA worldwide 11–17. In several studies,
telavancin MICs for MRSA ranged from two to eight
times lower than those observed for vancomycin,
teicoplanin, and linezolid [83]. Similarly, coagulase-
negative staphylococci (CoNS) exhibited MIC90 values
between 0.25 and 1 mg/L. Telavancin also proved to have
an excellent activity against MRSA and CoNS with re-
duced susceptibility to glycopeptides, together with both
vancomycin-susceptible and resistant enterococci [83].
The potent anti-staphylococcal activity of telavancin may
lead to consider this lipoglycopeptide as an alternative to
vancomycin in cases of difficult-to-treat MRSA infections
[84,85]. In fact telavancin has been associated with a ten-
fold greater peptydoglican synthesis inhibitory activity
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clinical trials demonstrated the efficacy and safety of
telavancin compared to vancomicin in the treatment of
nosocomial pneumonia [87,88].
Penetration into skin blister fluid was approximately
40% of plasma levels, but was sufficient to eradicate
pathogens which might be present. Telavancin pene-
trates the pulmonary epithelial lining fluid and alveolar
macrophages, with concentrations considerably higher
in the latter. Unlike daptomycin, the in vitro activity of
telavancin was found to be unaffected by pulmonary sur-
factant [83]. Given the excellent activity against MRSA
and other difficult Gram-positive bacteria, telavancin
seemed appropriate for treating complicated skin and
skin structure infections (cSSSI). Results from phase 2
and 3 clinical trials with telavancin for cSSSI have been
published and have demonstrated similar efficacy and
tolerability compared to standard anti-staphylococcal
beta-lactams and vancomycin.
Telavancin has been also evaluated in two studies in
the treatment of HAP due to Gram-positive cocci, par-
ticularly MRSA. The results of these two trials demon-
strated that telavancin has clinical response outcomes
that are non-inferior to those of vancomycin. More im-
portant, these findings, which incorporate data for more
than 1500 patients from >250 sites around the world,
are robust and consistent across all efficacy populations.
In patients with pre-existing moderate/severe renal im-
pairment (CrCl < 50 mL/min) telavancin presented an
increased mortality compare to vancomycin. [89].
Telavancin is usually well tolerated, with the most com-
monly experienced side effect being gastrointestinal dis-
comfort, but must be considered the potential elevation
of serum creatinine [90].
Telavancin has been approved by FDA for the treat-
ment of cSSSIs and by EMA for the treatment of adult
with nosocomial pneumonia including VAP, suspected
or known to be caused by MRSA, only in situations
where it is known or suspected that other alternatives
are not suitable.
Considering the limited therapeutic options for the
treatment of nosocomial pneumonia due to MRSA,
telavancin should represent a good alternative to stand-
ard therapy.
Dalbavancin is a new lipoglycopeptide that inhibits cell
wall synthesis in Gram-positive bacteria through the for-
mation of a stable complex between its heptapeptide back-
bone and the D-Ala-D-Ala portion of cell wall precursors.
Dalbavancin demonstrates in vitro activity against clinic-
ally significant Gram-positive pathogens, including MSSA,
MRSA, meticillin-susceptible S. epidermidis (MSSE),
meticillin-resistant S. epidermidis (MRSE) and entero-
cocci, but lacks activity against VanA-type enterococci
[91]. Dalbavancin MICs for Staphylococcus spp. aresignificantly lower than that of vancomycin. Dalbavancin
has been reported to be active against VISA, but shows
poor activity versus VRSA [92-94]. The activity of
dalbavancin against Clostridium spp. is comparable with
vancomycin [95].
Like other glycopeptides, dalbavancin is poorly
absorbed when administered orally, necessitating intra-
venous administration. The standard dose of dalbavancin
is 1000 mg administered on day 1 and 500 mg adminis-
tered 1 week later. The main PK characteristic is the
long-half-life: the terminal elimination half-life of
dalbavancin ranges from 147 to 258 hours, allowing the
once-weekly dosing that maintains the serum plasma
concentrations of dalbavancin above the MIC of com-
mon pathogens for 7 days [96]. The long-half life of
dalbavancin is a result of its extensive protein binding ,
as well as its retention within cells.
Two randomized phase III studies, one already pub-
lished and one not yet published, showed that dalbavancin
achieved its primary endpoint of non-inferiority in acute
bacterial SSTI. Researchers compared two intravenous
doses of dalbavancin given one week apart with twice-
daily vancomycin and linezolid doses. [97].
Polymixin
Polymyxins are antibiotics, with a general structure
consisting of a cyclic peptide with a long hydrophobic
tail. They disrupt the structure of the bacterial cell mem-
brane by interacting with its phospholipids. They are pro-
duced by non-ribosomal peptide synthetase systems in
Gram-positive bacteria such as Paenibacillus polymyxa
and are selectively toxic for Gram-negative bacteria
due to their specificity for the lipopolysaccharide mol-
ecule that exists within many Gram-negative outer
membranes.
The global problem of advancing antimicrobial resist-
ance has recently led to a renewed interest in their use.
CB-182,804 is a novel polymyxin analogue. It has a
good in vitro activity against MDR Gram-negative bac-
teria, such as A. baumannii, E. coli, K. pneumoniae and
P. aeruginosa. CB-182,804 has showed high activity
against colistin-susceptible and -resistant isolates.
Colistin-resistant strains that are resistant to all available
antibiotics are found to be susceptible, even if a cross re-
sistance with colistin has been observed [98]. Currently
the drug is in Phase I clinical stage.
Tetracycline
Tetracyclines are a group of broad-spectrum antibiotics
whose general usefulness has been reduced with the on-
set of bacterial resistance. Despite this, they remain the
treatment of choice for some specific indications. Tetra-
cyclines are generally used in the treatment of urinary
tract and intestinal infections, and are used in the
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allergic to β-lactams and macrolides; however, their use
for these indications is less popular than it once was due
to widespread development of resistance in the causative
organisms.
Eravacycline (TP-434) is a novel fluorocycline paren-
teral/oral antibiotic, similar to tigecycline, with a broad
spectrum activity against all Gram-negative bacteria. It is
active in vitro against MDR aerobic and anaerobic
Gram-negative and Gram-positive bacteria, including
emerging Gram-negative pathogens like Acinetobacter
baumanii (MIC90, 2 mcg/mL) and clinically important
species of Enterobacteriaceae (including E. coli [MIC90,
0.5 mcg/mL] or K. pneumoniae isolates [MIC90, 1 mcg/
mL] that produce extended spectrum beta-lactamases
[ESBL] and/or are carbapenem resistant. The drug has
low potency against Pseudomonas aeruginosa (MIC90,
16 mcg/mL), but it has no known antagonism with
other antibiotics that are expected to be active against
this species.
The spectrum includes MSSA/MRSA, MS/R S.
epidermidis, all the streptococci and enterococci, several
anaerobes, including Bacteroides spp. and Clostridium
difficile [99]. The mean half-life of everacycline in
plasma was 47.7 hours whereas the median value was
35.3 hours. Oral bioavailability would provide an import-
ant dosing advantage for a tetracycline that has activity
against MDR Gram-negative bacteria. The oral bioavail-
ability in humans averaged about 28% for doses of 50,
100, 200, and 300 mg and oral doses were well-tolerated.
Two IV doses of 1.5 mg/kg q24h and1.0 mg/kg q12h,
are currently being evaluated in a phase 2 randomized,
double-blind, global study for the treatment of adult
cIAI [100,101].
Omadacycline (PTK796)
Omadacycline, an aminomethylcycline, is a semisynthetic
derivative of minocycline that has in vitro potency against
Gram-positive and Gram-negative bacteria. It presents ac-
tivity against MSSA/MRSA, MS or MR coagulase-negative
staphylococci, Enterococcus faecalis, Enterococcus faecium,
S. pneumonia, Klebsiella pneumoniae, Proteus mirabilis/
vulgaris, Providencia rettgeri/stuartii, Morganella morganii
and Bacteroides fragilis. The potency of omadacycline was
not impaired by lung surfactant [102].
In a phase 2 study of over 200 adults with SSSI initially
requiring IV therapy, patients were randomized to re-
ceive 100 mg q24h IV with 200 mg oral step-down dos-
ing or linezolid at 600 mgq12h IV with a 600 mg q12h
oral step-down dose. Omadacycline showed comparable
efficacy across all the study populations [102].
Omadacycline started enrollment in a phase 3 ABSSSI
trial in 2009 with 200 mg IV, with potential to step-
down to a 150 mg oral tablet, but the trial was stoppedto change their endpoints in the protocol to be as re-
quired by the new FDA guidance for trial on cSSTI.Pleuromutilin compound
Pleuromutilins were discovered as natural-product anti-
biotics in 1950. Tiamulin was the first pleuromutilin
compound to be approved for veterinary use in 1979,
followed by valnemulin in 1999. It was not until 2007
that retapamulin became the first pleuromutilin ap-
proved for use in humans. However, retapamulin is lim-
ited to topical application. Recent advances in lead
optimization have led to the synthesis of pleuromutilins
that combine potent antibacterial activity with favorable
pharmaceutical properties, making these compounds
suitable for oral and intravenous delivery. Most
pleuromutilins have an antibacterial spectrum that
covers the common pathogens involved in both skin and
respiratory tract infections.
BC-3781 is a novel semisynthetic systemic agent be-
longing to the pleuromutilin class of antibiotics.
Pleuromutilins interferes with bacterial protein synthesis
via a specific interaction with the 23S rRNA of the 50S
bacterial ribosome subunit. In vitro, BC-3781 demon-
strates clinically relevant activity against the most fre-
quently identified Gram-positive skin pathogens, including
MSSA and MRSA, S. pyogenes, Streptococcus agalactiae,
and vancomycin-resistant Enterococcus faecium. Further-
more, BC-3781 exhibits significant in vitro activity against
coagulase-negative Staphylococcus spp. and communitary
respiratory pathogens, including Streptococcus pneumoniae,
Haemophilusinfluenzae, Moraxella catarrhalis, Legionella
pneumophila, Chlamydophila pneumoniae, and Myco-
plasma pneumoniae [103,104] So far the therapeutic ad-
ministration of pleuromutilin antibiotics has been limited
to veterinary medicine or to the topical route in humans,
due to associated toxicities.
Recently the phase 2 study in the treatment of cSSTI
caused by a Gram-positive pathogen has been completed
by comparing BC-3781 to vancomycin. The results pro-
vided the first proof of concept for the systemic use of a
pleuromutilin antibiotic in the treatment of SSSIs [105].Conclusions
The creation of new antibiotics targeting the growing
threat of multidrug resistance is a goal that remains
"alarmingly elusive”. In a recent article, the IDSA reports
that only a single new antibiotic has been approved by
FDA since 2010, and few new drugs are in the pipeline.
The report found also that only 7 new antibiotics
targeting MDR Gram-negative bacilli have reached phase
2 or phase 3 trials since 2010, when IDSA established its
10 × '20 initiative, with the goal of developing 10 new an-
tibiotics by 2020 [106].
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70′s and the 80′s, the ability to find new compounds
and/or modify structural forms to extend the spectrum
against resistant strains was possible and is still being
pursued today. Low returns on investments and an un-
predictable and often infeasible approval pathway at
regulatory agencies have caused many companies to
leave the antibiotics market. Resistance is the driver for
new antibiotics and the incidence of MDR pathogens is
ever increasing, despite the attempts of antibacterial
stewardship and stringent effort to infection-control of
MDR bacteria in hospital. The bad hospital pathogens
have escaped the hospital and are joining the ranks of
the community pathogens.
There is a number of promising antibiotics in develop-
ment, regulatory approvals are crucial over the next five
years to return us to a time when reliably effective treat-
ment of bacterial diseases is again a reality, not just a fu-
ture prospect.
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